StockWatch
·

Oriental Aromatics Ltd-$ Q2 FY27 Results

OALQ2 FY27 Results
Filing
Result:Good· Market: Down#Margin expansion#Base effect

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue318.2022.5%17.3%
Total Income318.6922.2%16.2%
Expenditure309.3721.1%13.9%
PBT9.3376.9%243.2%
Net Profit5.79130.2%683.9%
OPM7.94%0.32pp1.58pp
NPM1.82%0.86pp1.55pp
EPS1.72129.3%681.8%
View full financials

Chemicals: revenue grew a healthy 17.3% YoY with OPM expanding ~158bps (6.36%→7.94%) and NPM more than 6x, but the eye-catching 684% PAT growth is mostly a depressed prior-year base rather than a standout absolute margin, so it's rated good rather than very_good.

ORIENTAL AROMATICS LTD · Q2 FY-2027 · THE VERDICT

Record Revenue, Margin Gains—but Mahad Keeps the Verdict at Hold

Oriental Aromatics delivered its highest-ever quarterly revenue (₹318 Cr, +17% YoY) and expanded EBITDA margins 158 bps, yet guided steady-state growth of 10–12%—not higher. The call explains why: Mahad facility losses will drag profitability for 2–3 more quarters.

07 Nov 2026 · 6 min read
Reported Q2 Revenue

₹318.2 Cr

+17.3% YoY, +22.5% QoQ

Reported Q2 PAT

₹5.8 Cr

1.8% margin; +128% YoY Q2-on-Q2

Q2 EBITDA margin

7.9%

+158 bps YoY

Standalone EBITDA margin

8.6%

Gap to consolidated 7.8% = Mahad drag

Oriental Aromatics closed Q2 with its highest quarterly revenue on record. The numbers look sharp on the headline: ₹318 Cr revenue, EBITDA margin of 7.9%, and PAT climbing 128% year-on-year. But step past the poster and the story tightens. Management declined to raise full-year guidance—instead reaffirming 10–12% steady-state growth from the prior call's 10–15% range. On a call where headline PAT growth is 128%, that feels reserved. It's not caution for caution's sake. It's Mahad.

The PAT Quality Issue: Low Base, Mahad Anchor

H1 PAT grew 592% year-on-year (₹8.3 Cr vs ₹1.2 Cr), which sounds extraordinary. It's not. The prior-year H1 base was a rounding error—Q1 FY'27 itself was only ₹2.48 Cr. Even on a standalone quarterly view, Q2 PAT at 128% YoY growth is impressive but lap-sensitive; it's also lapped a ₹2.5 Cr prior-year Q2. Strip the accounting: consolidated EBITDA margin of 7.8% sits 80 basis points below the standalone Amberath–Baroda–Bareilly facilities, which clock 8.6%. The gap is Mahad, the specialty aroma ingredients facility at Mahad. It runs at 50–55% of installed capacity, loses money, and will continue to drag consolidated profitability for 2–3 more quarters until it reaches 75–80% utilization and EBITDA neutrality. That timeline is management's own, not market consensus.

Revenue, though, is genuinely strong. H1 revenue of ₹578 Cr is up 16.3% year-on-year—already ahead of the prior call's guided 10–15% range for the full year. Q2 pushed higher on Fragrance division momentum (Amberath: +20% sales QoQ), industrial customer allocations ramping from prior RFQ cycles, and operational efficiency. Cash profit expanded 32.7% QoQ to ₹13.58 Cr, a positive signal on working-capital discipline.

Management claims vs. the data

Highest-ever quarterly revenue ₹318.19 Cr; +17% YoY, +22% QoQ

Delivered ₹318.2 Cr, 17.3% YoY, 22.5% QoQ

Supported

Q2 EBITDA margin improved to 7.94%, +158 bps YoY

Delivered 7.9%; EBITDA ₹25.26 Cr vs ₹17.2 Cr prior year

Supported

H1 revenue ₹578 Cr, +16.3% YoY; EBITDA margin 7.8%

Matches; H1 EBITDA ₹45.07 Cr vs ₹35.31 Cr FY'26 (+27.6%)

Supported

Mahad production +51% QoQ, sales +74% QoQ; still sub-optimal at 50–55%

Confirmed; management reaffirmed 75–80% target in 2–3 quarters

Supported

Unilever technical & manufacturing partnership announced

Confirmed as MoU-stage. Scope (CDMO/CMO), timeline, capex unquantified

Supported (but unproven)

What Changed This Quarter

The Unilever announcement is the strategic milestone. Management confirmed a technical, strategic, and manufacturing arrangement with Unilever Industries Private Limited—described as early-stage, structured as a Memorandum of Understanding. CEO Parag Satoskar declined to quantify scope, capex, timeline, or revenue contribution, citing confidentiality and MoU stage. Parag offered that it 'could take a couple of years to shape' and is framed as a long-term opportunity, not a near-term revenue driver. Investors pressed on structure (CDMO, CMO, co-invest?); the company held the line on 'more information when formalized.' This is neither a deal-risk nor a deal-done—it's a strategic signal that the internalization thesis (backward integration into specialty aroma ingredients) is attracting large FMCG partners. Execution remains to be seen.

On Mahad itself, no change to prior guidance. The facility continues to ramp (Q2 sales +74% QoQ from a low base), but utilization remains at 50–55% vs the 75–80% breakeven target. Management reaffirmed the 2–3-quarter timeline but offered no drill-down on customer allocations or contingency plan if the ramp slips. This persistence of the drag—acknowledged by CFO Shyamal Bodani as 'continues to be a drag on consolidated profitability'—is the reason guidance remained anchored at 10–12% growth and a 10% EBITDA margin target, not raised.

The Bull-Bear Ledger

What the numbers argue for and against
  • Revenue growth beats prior guidance; H1 at 16.3% vs prior 10–15% range

  • EBITDA margin expanded 158 bps YoY despite raw material inflation (alpha-pinene, terpenes)

  • Fragrance division momentum (+7% H1 YoY, +20% Q2 QoQ sales); internalization program strengthening

  • Cash profit strong; working capital management intact despite higher inventory (RM inflation)

  • PAT growth headline inflated by low prior-year base; H1 comp was ₹1.2 Cr

  • Mahad operating at loss; will drag consolidated profitability 2–3 more quarters

  • Consolidated EBITDA margin (7.8%) sits 80 bps below standalone (8.6%); gap is pure Mahad drag

  • Camphor division facing structural headwinds: Q2 sales -5% QoQ, -8% YoY due to alpha-pinene inflation and price sensitivity in pooja market

  • Unilever partnership remains MoU-stage; unquantified and multi-year away from commercial shape

  • Net debt-to-equity rose to 0.64 from 0.56; driven by higher inventory and Q-end receivables spike

Risks, Ranked by Holder Concern

What should worry a holder—and why

Mahad profitability timeline slip

High

Facility loss-making at 50–55% utilization; target 75–80% in 2–3 quarters. If ramp delays, consolidated margin stays compressed 7–8% range instead of recovering to 10% target. Each quarter of delay is ₹1–1.5 Cr in embedded losses.

Raw material inflation may not fully pass through

High

Alpha-pinene (Camphor feedstock), terpenes, petrochemicals remain elevated. Pooja market and commodity Camphor segment have zero pricing power; Q2 Camphor sales down 8% YoY despite cost inflation. Competitive intensity and customer pressure may cap margin recovery.

Unilever execution risk

Medium

Partnership at MoU stage; scope and capex unquantified. If formalization stalls or scope shrinks, the strategic rationale (backward-integrated ingredients supply to FMCG anchor) becomes speculative. Currently priced in as 'long-term opportunity,' but credibility hangs on commercial progress.

Camphor market structural overcapacity

Medium

Domestic Camphor market faces structural overcapacity and Chinese import competition. Bareilly facility is a mature cash-generator but a low-growth, low-margin anchor. No path to premium pricing unless entire industry consolidates or global alpha-pinene costs normalize.

Working capital deterioration under RM inflation

Medium

Net debt-to-equity rose to 0.64 from 0.56 in one quarter. If raw material costs remain elevated and inventory buildup persists, debt could rise further, constraining capex flexibility and financial headroom for Mahad ramp investments.

How the Street Is Reading It

The market's response was cool. On day 1 (result announced Nov 4, 2026, pre-close ₹564.7), the stock fell 2.6%, suggesting the street discounted the headline beat. Current price of ₹497 (as of Nov 6) sits well below the stock's key moving averages: SMA20 (₹574), SMA50 (₹537)—both crossed downward. Relative to the 52-week range of ₹228–₹639, the stock is in the lower third. Most striking: it remains down 54.82% from its all-time high of ₹1,100, a structural reset from prior euphoria. RSI of 38.5 signals oversold but not capitulation.

Ownership remains heavily promoter-locked at 74.17% (unchanged across recent quarters). FII holding is negligible (0.02% as of Q1 FY'27, up just 2 basis points). DII presence is nil. The lack of institutional ownership—despite record revenue—suggests the street is waiting for two things: (1) Mahad to prove it can ramp to breakeven on schedule, and (2) Unilever partnership to crystallize into concrete commercial terms. The stock's posture—below moving averages, light institutional flow, heavy promoter anchor—is characteristic of a company in transition: operationally improving, but profitability visibility impaired by one major facility drag and one unproven strategic partnership.

The Debate

What to Watch Next

Three concrete things that resolve the debate
  • 1 · Mahad utilization progression in Q3

    Watch for utilization moving from 50–55% toward 60%+ and gross margin turning positive. If utilization is still sub-55% by Q3, the 75–80% target in '2–3 quarters' is slipping. This is the biggest profitability lever.

  • 2 · Unilever partnership structure & capex commitment

    The next earnings call or investor update should detail scope (CDMO, CMO, equity stake?), initial capex, and timeline to first commercial allocation. Any delay in formalization or capex reduction signals strategic pivot, not commitment.

  • 3 · Raw material normalization & Camphor volume recovery

    Camphor sales are down 8% YoY due to alpha-pinene inflation and pooja market price resistance. Track whether global alpha-pinene prices ease in H2 and whether Camphor volume rebounds. If RM inflation persists, margin recovery is further deferred.

Oriental Aromatics delivered a record revenue quarter, expanded margins, and beat prior guidance—operationally it's a solid quarter. But the company held guidance steady rather than raise it, the reason being Mahad: a facility that operates at a loss and will continue to drag consolidated profitability for 2–3 quarters as it ramps to breakeven utilization. PAT growth looks exceptional on the headline but rests on a low prior-year base; organic run-rate is much steadier. Unilever is a strategic signal but unquantified and years away from revenue shape.

This is steady execution, not a step-change. The company is worth owning on completion of Mahad's ramp-up and Unilever partnership formalization—likely 3–4 quarters ahead. For now, Hold. The number to track from here is Q3 Mahad utilization: if it's moving toward 60%+, the inflection case stays intact. If it stalls below 55%, Mahad becomes a structural drag, not a temporary one.

Informational and educational content only. Not investment advice.